Home > Insider Trading > Filing (0001104659-18-025864)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1718108	Surface Oncology Inc.	SURF	Pharmaceutical Preparations (2834)	V8

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1114448	Ag Novartis	Lichtstrasse 35 Basel V8 CH 4056		No	No	Yes	No
1673852	Novartis Institutes For Biomedical Research, Inc.	250 Massachusetts Avenue Cambridge MA 02139		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-04-23	2,272,726	$0.00	2,272,726	No	4	C	Direct
Common Stock	Acquisiton	2018-04-23	909,090	$0.00	3,181,816	No	4	C	Direct
Common Stock	Acquisiton	2018-04-23	766,666	$15.00	3,948,482	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2018-04-23	1,571,429	$0.00	2,272,726	$0.00
Common Stock	Series A-1 Preferred Stock	Disposition	2018-04-23	5,214,286	$0.00	909,090	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0			No	4	C	Direct

Footnotes

The 1,571,429 shares of Series A Preferred Stock held by the Reporting Person automatically converted upon the closing of the Issuer's initial public offering into 2,272,726 shares of the Issuer's Common Stock without payment or further consideration.
The 5,214,286 shares of Series A-1 Preferred Stock held by the Reporting Person automatically converted upon the closing of the Issuer's initial public offering into 909,090 shares of the Issuer's Common Stock without payment or further consideration.
The shares are held directly by Novartis Institutes for BioMedical Research, Inc. ("NIBRI"). NIBRI is an indirect wholly-owned subsidiary of, and controlled by, Novartis AG.
Not applicable.